GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK1349572 Drug Interaction Study With Etravirine
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00774111
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
GSK1349572 Drug Interaction Study With Protease Inhibitors
- Conditions
- Healthy SubjectsInfection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00774735
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.
- Conditions
- Hepatitis B
- Interventions
- Biological: EngerixTM-B
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 49
- Registration Number
- NCT00774995
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
- Conditions
- Influenza
- Interventions
- Biological: GSK Biologicals' Fluarix™Biological: Influenza vaccine GSK2186877A
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 971
- Registration Number
- NCT00772889
- Locations
- 🇳🇴
GSK Investigational Site, Skien, Norway
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
- Conditions
- Influenza
- Interventions
- Biological: GSK A/turkey H5N1 Influenza vaccine
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 469
- Registration Number
- NCT00771615
- Locations
- 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada
Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 190
- Registration Number
- NCT00766090
- Locations
- 🇺🇸
GSK Investigational Site, Waco, Texas, United States
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
- Conditions
- Influenza
- Interventions
- Biological: FluarixBiological: Fluzone
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3317
- Registration Number
- NCT00764790
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
- Conditions
- Influenza
- Interventions
- Biological: GSK Biologicals' influenza vaccine GSK2186877ABiological: GSK Biologicals' Fluarix
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 192
- Registration Number
- NCT00765076
- Locations
- 🇪🇸
GSK Investigational Site, Marid, Spain
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
- Conditions
- Influenza
- Interventions
- Biological: GSK Bio's influenza vaccine GSK2186877ABiological: Fluarix
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 526
- Registration Number
- NCT00760617
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612Biological: Pneumococcal vaccine GSK1024850A
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 363
- Registration Number
- NCT00758264
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan Hsien, Taiwan